Current HDAC Inhibitors in Clinical Trials

Area of Science:

• Molecular Biology
• Epigenetics
• Pharmacology

Background:

• Epigenetic modifications, including histone deacetylase (HDAC) activity, regulate gene expression and are implicated in disease pathogenesis.
• Aberrant HDAC expression is linked to various cancers and neurodegenerative disorders, establishing HDACs as critical therapeutic targets.

Purpose of the Study:

• To review HDAC classes and isoforms.
• To discuss class- or isoform-selective HDAC inhibitors (HDACi) in late-stage preclinical and clinical development.
• To highlight pharmacokinetic challenges and future directions in HDACi drug design.

Main Methods:

• Literature review of HDACs and HDAC inhibitors.
• Analysis of preclinical and clinical data for HDACi.
• Discussion of pharmacokinetic properties and drug development strategies.

Main Results:

• HDACs represent a significant class of epigenetic targets with established roles in disease.
• Numerous HDAC inhibitors are in clinical trials for cancer treatment, with some already FDA-approved.
• Selective HDACi targeting specific classes or isoforms show promise for improved therapeutic outcomes.

Conclusions:

• HDAC inhibitors offer a promising therapeutic strategy for cancer and other diseases.
• Further research into selective HDACi and overcoming pharmacokinetic hurdles is crucial for advancing drug development.
• Optimizing HDACi design holds potential for more effective and safer treatments.